Search

Pacific Biosciences of California Inc

Suletud

SektorTervishoid

2.16 3.35

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.9100000000000001

Max

2.18

Põhinäitajad

By Trading Economics

Sissetulek

-45M

-53M

Müük

1.8M

39M

Aktsiakasum

-0.14

Kasumimarginaal

-135.914

Töötajad

485

EBITDA

-32M

-38M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

-3.06% downside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

4. nov 2026

Turustatistika

By TradingEconomics

Turukapital

131M

572M

Eelmine avamishind

-1.19

Eelmine sulgemishind

2.16

Pacific Biosciences of California Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

21. okt 2026, 23:16 UTC

Pacific Biosciences of California Inc is trading modestly higher in after-market hours, marking its fifth consecutive session of gains.

20. okt 2026, 23:16 UTC

Pacific Biosciences of California Inc is trading modestly higher in after-market hours following Tuesday's close, amid ongoing volatility within its one-month trading range.

19. okt 2026, 20:07 UTC

News

Pacific Biosciences announces a multi-year collaboration with Verily Health to integrate HiFi sequencing technology with Verily's AI platform for clinico-genomic datasets.

16. okt 2026, 23:06 UTC

Pacific Biosciences of California Inc is effectively unchanged in after-market trading, having retraced from earlier highs amid recent declines below its 20-day moving average.

15. okt 2026, 23:02 UTC

Correlated Moves

After-market hours, the ARK Genomic Revolution ETF (ARKG) is trading higher, supported by a Neutral rating for CRISPR Therapeutics from UBS and gains in key holdings.

14. okt 2026, 23:21 UTC

Pacific Biosciences shares declined in after-market trading, marking the fourth consecutive session of lower prices, reaching a recent low shortly before the latest timestamp.

13. okt 2026, 23:06 UTC

Pacific Biosciences of California Inc's shares were roughly flat in after-market trading, following three consecutive lower daily closes while remaining above the 20-day moving average.

12. okt 2026, 22:16 UTC

Pacific Biosciences of California Inc is trading roughly flat in after-market hours, with the stock positioned around the middle of its one-month range.

9. okt 2026, 20:07 UTC

News

UBS initiated coverage of Pacific Biosciences with a Neutral rating and a price target of $1.35, adjusting its Fair Value estimate to $2.40 per share.

8. okt 2026, 23:20 UTC

Pacific Biosciences shares declined significantly in after-market trading, reversing earlier gains and marking a notable drop compared to Thursday's close.

7. okt 2026, 23:06 UTC

Pacific Biosciences of California Inc declined during after-market hours on Wednesday, retracing significantly from its prior close despite strong recent performance.

6. okt 2026, 23:06 UTC

Pacific Biosciences of California Inc declined in after-market trading, moving lower since Tuesday's close, despite strong performance over the past month.

5. okt 2026, 20:03 UTC

Pacific Biosciences of California Inc is higher in Monday's trading, continuing its upward trend since Friday, despite earlier pulling back from a session high.

2. okt 2026, 20:00 UTC

Pacific Biosciences of California Inc is trading higher on Friday, maintaining gains above its 20-day moving average despite a recent pullback.

1. okt 2026, 23:05 UTC

Pacific Biosciences of California Inc's shares showed little change in after-market trading, remaining near Thursday's close after a brief uptick.

30. sept 2026, 23:01 UTC

Pacific Biosciences of California Inc declined sharply in after-market trading, contrasting with its recent upward trend, but remains above its 20-day moving average.

29. sept 2026, 23:16 UTC

Pacific Biosciences of California Inc's shares are trading lower in after-market hours, retracing from a flat position since Tuesday's close.

28. sept 2026, 20:07 UTC

Pacific Biosciences of California Inc is advancing, reflecting broader market gains since Friday, despite pulling back from a session high earlier today.

25. sept 2026, 23:51 UTC

Pacific Biosciences of California Inc is trading lower in after-market hours, reflecting a notable decline since Friday's close and today's sharp loss.

24. sept 2026, 23:01 UTC

Pacific Biosciences of California Inc is declining in after-market trading, falling significantly from Thursday's close, despite being above its 20-day moving average.

23. sept 2026, 20:07 UTC

Correlated Moves

Pacific Biosciences is sharply lower, following a broader market decline and significant losses in key holdings of the ARK Genomic Revolution ETF.

22. sept 2026, 23:06 UTC

Pacific Biosciences of California Inc is trading lower in after-market hours, having declined from earlier gains and remaining above its 20-day moving average.

21. sept 2026, 22:35 UTC

In after-market trading, Pacific Biosciences of California Inc is roughly flat since Monday's close, reflecting routine performance near the lower end of its one-month range.

18. sept 2026, 23:51 UTC

Pacific Biosciences of California Inc declined during after-market trading, moving lower since Friday's close and currently below its 20-day moving average.

17. sept 2026, 20:02 UTC

Macro Event
Correlated Moves

Pacific Biosciences is sharply higher, reflecting a positive trend in the life sciences sector, alongside gains in the ARK Genomic Revolution ETF.

16. sept 2026, 23:16 UTC

Pacific Biosciences of California Inc is trading roughly flat in after-market hours, remaining below its 20-day moving average after four consecutive higher sessions.

15. sept 2026, 23:11 UTC

Pacific Biosciences of California is gaining in after-market trading, supported by a positive performance backdrop and four consecutive higher closes.

14. sept 2026, 20:05 UTC

Correlated Moves

Pacific Biosciences of California is higher today, influenced by social media discussions on Tempus AI's $80 price target and broader market sentiment.

11. sept 2026, 19:02 UTC

Pacific Biosciences of California is trading higher, continuing its recovery after three sessions of declines. No specific news was identified for the upward movement.

9. sept 2026, 20:01 UTC

News

Pacific Biosciences of California shares are lower after UBS initiated coverage with a Neutral rating and a price target of $1.35.

Võrdlus sarnastega

Hinnamuutus

Pacific Biosciences of California Inc Prognoos

Hinnasiht

By TipRanks

-3.06% langus

12 kuu keskmine prognoos

Keskmine 1.9 USD  -3.06%

Kõrge 3 USD

Madal 1.25 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Pacific Biosciences of California Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

2

Osta

2

Hoia

1

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat